演題詳細

ポスター / Poster

ポスター 23 (Poster 23) :低悪性度B細胞リンパ腫:ベンダムスチン

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
瀧本 理修 (Rishu Takimoto):1
1:札幌医科大学医学部附属病院 腫瘍・血液内科
 
前へ戻る

Bendamustine plus Rituximab treatment for relapsed or refractory Waldenström's macroglobulinemia

演題番号 : PS-1-166

宮園 卓宜 (Takayoshi Miyazono):1、在田 幸太郎 (Kotaro Arita):1、和田 暁法 (Akinori Wada):1、村上 純 (Jun Murakami):1、林 伸一 (Shinichi Hayashi):2、野本 一博 (Kazuhiro Nomoto):2、井村 穣二 (Jouji Imura):2、杉山 敏郎 (Toshiro Sugiyama):1

1:Department of Gastroenterology and Hematology, University of Toyama, Japan、2:Laboratory of Pathology ,Toyama University Hospital, Japan

 

Background: Bendamustine is a novel alkylating agent for the treatment of indolent lymphoma. In this paper,we report 3 cases of treated bendamustine plus rituximab (BR) to relapsed or refractory Waldenström's macroglobulinemia (WM). Case 1: A 78-y.o. male was diagnosed as WM 15 years ago. He received treatment with cyclophosphamide (CPM) intermittently at the long period. He has shown anemia, lymphadenopathy, and hepatomegaly from April 2012, and started treatment with BR. Case 2: A 56-y.o. male was diagnosed as WM with both leg numbness, axillary lymphadenopathy, splenomegaly and cardiac dysfunction. He received treatment with rituximab twice and then treated with BR. Case 3: A 72-y.o. female was diagnosed as WM with pulmonary arterial hypertension (PAH). Her symptoms for PAH has improved after rituximab plus CPM plus dexamethasone (RCD) treatments. The serum IgM is still high (2702 mg/dl), she started BR treatment. Result: The effects of all cases were more than PR and their symptoms had improved after BR treatment. Myelosuppression was prolonged in case 1. CMV infection developed during BR treatment in case 2. Bendamustine did a dose reduction due to leukopenia in Case 2 and 3. Conclusion: BR treatment is effective for relapsed or refractory WM. Infection control due to leuko- and lymphocyto-penia might be essential in BR treatment.

前へ戻る